

Resource Summary Report

Generated by [dkNET](#) on Sep 20, 2026

NCI-H929

RRID:CVCL_1600

Type: Cell Line

Proper Citation

RRID:CVCL_1600

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1600

Proper Citation: RRID:CVCL_1600

Description: Cell line NCI-H929 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Plasma cell myeloma

Defining Citation: [PMID:2423157](#), [PMID:3275865](#), [PMID:8806089](#), [PMID:8806092](#), [PMID:8943038](#), [PMID:10087940](#), [PMID:10936422](#), [PMID:11157491](#), [PMID:12068308](#), [PMID:16956823](#), [PMID:17171682](#), [PMID:17692805](#), [PMID:18647998](#), [PMID:18700954](#), [PMID:19306352](#), [PMID:21173094](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25688540](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30285677](#), [PMID:30545397](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:32123307](#), [PMID:35839778](#)

Comments: Characteristics: Produces IgA kappa., Population: Caucasian., Part of: RAS genetic alteration cell panel (ATCC TCP-1031)., Part of: MYC genetic alteration cell panel (ATCC TCP-1035)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H929

Synonyms: NCI H929, NCIH929, H929, H-929

Cross References: BTO:BTO_0002416, CLO:CLO_0008127, EFO:EFO_0001221, CLDB:cl3661, CLDB:cl3662, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770,

ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-1088, ATCC:CRL-3580, ATCC:CRL-9068, BCRC:60386, BioSample:SAMN03473361, BioSample:SAMN10988115, cancercellines:CVCL_1600, CCRID:1101HUM-PUMC000360, CCRID:4201HUM-CCTCC00300, CCTCC:GDC0300, Cell_Model_Passport:SIDM01148, ChEMBL-Cells:ChEMBL4295412, ChEMBL-Targets:ChEMBL4296391, CLS:305236, Cosmic:720769, Cosmic:724825, Cosmic:759905, Cosmic:760391, Cosmic:760392, Cosmic:886085, Cosmic:888022, Cosmic:1070716, Cosmic:1424217, Cosmic:2081399, Cosmic:2302415, Cosmic:2367293, Cosmic:2391791, Cosmic:2809759, Cosmic-CLP:724825, DepMap:ACH-000050, DSMZ:ACC-163, DSMZCellDive:ACC-163, ECACC:95050415, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS197CBA, ENCODE:ENCBS571AQH, GDSC:724825, GEO:GSM143333, GEO:GSM290290, GEO:GSM562817, GEO:GSM887452, GEO:GSM888532, GEO:GSM1374767, GEO:GSM1670271, IARC_TP53:28520, LiGeA:CCLE_061, Lonza:47, PharmacDB:NCIH929_1149_2019, PRIDE:PXD030304, Progenetix:CVCL_1600, PubChem_Cell_line:CVCL_1600, Wikidata:Q54908142

ID: CVCL_1600

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260920T004619+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H929.

No alerts have been found for NCI-H929.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 474 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#).

Jiang K, et al. (2026) The Histone Modifier KANSL2 Is an Actionable Biomarker in Multiple Myeloma. *Molecular cancer therapeutics*, 25(6), 1016.

Ng HL, et al. (2026) BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(25), e17231.

Tang A, et al. (2026) Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. *Cell reports. Medicine*, 7(3), 102628.

Fang C, et al. (2026) Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. *Cancer research*, 86(8), 1956.

- Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. *Cell reports*, 45(6), 117464.
- Ghaemi B, et al. (2026) Precision radiolabeled B-cell maturation nanobody for targeted PET imaging and radioligand therapy of disseminated multiple myeloma. *Theranostics*, 16(6), 2748.
- Lin P, et al. (2026) CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models. *Blood cancer discovery*, 7(2), 234.
- Wang L, et al. (2025) Targeting of the CD161 Inhibitory Receptor Enhances Bone-Marrow-Resident Memory CD8+ T-Cell-Mediated Immunity against Multiple Myeloma. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(42), e10888.
- Yin Z, et al. (2025) Cinobufagin overcomes bortezomib resistance in multiple myeloma strains by targeting SEC62/TRPM4-mediated NECSO. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 147, 157171.
- Lowe E, et al. (2025) Preclinical characterization of novel multi-client inhibitors of Sec61 with broad antitumor activity. *The Journal of pharmacology and experimental therapeutics*, 392(8), 103634.
- Hussain T, et al. (2025) Therapeutic potential of PRMT1 as a critical survival dependency target in multiple myeloma. *BMC cancer*, 25(1), 1704.
- Tran S, et al. (2025) Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma. *Blood neoplasia*, 2(1), 100050.
- Wu D, et al. (2025) Optimization of a novel 2+2 BCMA x CD3 bispecific antibody for minimized cytokine release and potent efficacy. *Molecular cancer therapeutics*.
- Xu J, et al. (2025) IGF2BP1 promotes multiple myeloma with chromosome 1q gain via increasing CDC5L expression in an m6A-dependent manner. *Genes & diseases*, 12(1), 101214.
- Oikonomidi I, et al. (2025) Interferon regulatory factor 4 mediates nonenzymatic IRE1 dependency in multiple myeloma cells. *PLoS biology*, 23(4), e3003096.
- Krishnamoorthy M, et al. (2025) Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. *Frontiers in immunology*, 16, 1518787.
- Nardone C, et al. (2025) Structural basis for the midnolin-proteasome pathway and its role in suppressing myeloma. *Molecular cell*, 85(13), 2597.
- Yao R, et al. (2025) Identification of a new micropeptide altKLF4 derived from KLF4 that influences myeloma chemotherapeutic sensitivity. *Cellular signalling*, 131, 111767.
- Simon S, et al. (2025) Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy. *Nature cancer*, 6(4), 647.
- Domagala J, et al. (2025) Ammonia Suppresses the Antitumor Activity of Natural Killer Cells and T Cells by Decreasing Mature Perforin. *Cancer research*, 85(13), 2448.